Company News

11/05/2022

EARLY GENETIC TESTING PREDICTS HEART DISEASE AND NOVEL THERAPIES FOR WOMEN WITH LUPUS

CHARLOTTESVILLE, Va., /PRNewswire/ — AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.  Shared genes that predispose both to lupus and cardiovascular disease are revealed in the peer-reviewed journal Cell Reports Medicine.  AMPEL’s breakthrough approach characterizes inherited

11/02/2022

New Jeeva eClinical Research Technology Enables Global Diversity Inclusion and Multi-Center Collaboration

MANASSAS, VA. (PRWEB) – Diversity and inclusion in clinical trials are critical to achieving accurate and reliable results.(1) Participation in clinical trials is voluntary, and individuals of different ages, genders, races, ethnicities, genetic backgrounds, geographic locations, and environments will respond differently to the same treatments. An effective way to achieve diversity in clinical trials is

10/26/2022

AgroSpheres Raises $22 million Series B to Accelerate Commercialization and Manufacturing of Reliable Biobased Solutions

CHARLOTTESVILLE, VA – AgroSpheres, a leader in developing the next generation of environmentally friendly crop health products, announced today that it had raised $22 million in a Series B financing round led by Lewis & Clark AgriFood and Ospraie Ag Science. Bidra Innovation Ventures and its existing investor, Cavallo Ventures, participated in the financing round.

10/04/2022

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions, Inc announced that the U.S. Patent & Trademark Office (PTO) issued a notice of allowance for a patent covering methods for detection of mild traumatic brain injury (mTBI), also known as concussion, using Brain Derived Neurotrophic Factor (BDNF). BDNF is an important component of the biomarker panel in the multi-modal diagnostic prognostic and

10/02/2022

Serpin Pharma completes Phase 1b/2a SPIRIT Clinical Trial

Serpin Pharma, a clinical-stage biotech company developing first in class drugs to treat human diseases caused by inflammation, reported data from its Phase 1b/2a clinical trial. The results, published in the Journal of Cardiovascular Pharmacology, report the effects of a single subcutaneous administration of SERPIN drug (SP16), a synthetic, selective LRP1 agonist, in ten patients

09/30/2022

Virginia Beach Enters into Bilateral Agreements with International Biomedical & Life Sciences Clusters

​The Department of Economic Development and the City of Virginia Beach have recently signed two Memoranda of Understanding (MOUs) with Biomedical & Life Sciences clusters during a recent marketing mission to Spain. These bilateral agreements will create and encourage collaboration between the four signatory parties and favor the generation of ideas that will in turn